ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data

Arrowhead Pharmaceuticals (ARWR) stock had its best day in nearly 8 months after an analyst raised the price target.

Chardan analyst Keay Nakae increased the price target on Arrowhead to $115 from $90, maintaining a Buy rating.

The price target hike was driven by data on plozasiran, an Arrowhead drug candidate.